CY1123942T1 - Συνθεσεις ωμεγα-3 λιπαρων οξεων για τη θεραπεια ασθενειων που επιφερουν βλαβη στο νευρικο συστημα - Google Patents

Συνθεσεις ωμεγα-3 λιπαρων οξεων για τη θεραπεια ασθενειων που επιφερουν βλαβη στο νευρικο συστημα

Info

Publication number
CY1123942T1
CY1123942T1 CY20201100758T CY201100758T CY1123942T1 CY 1123942 T1 CY1123942 T1 CY 1123942T1 CY 20201100758 T CY20201100758 T CY 20201100758T CY 201100758 T CY201100758 T CY 201100758T CY 1123942 T1 CY1123942 T1 CY 1123942T1
Authority
CY
Cyprus
Prior art keywords
omega
treatment
nervous system
fatty acid
causing damage
Prior art date
Application number
CY20201100758T
Other languages
English (en)
Inventor
Tassos GEORGIOU
Original Assignee
Tassos GEORGIOU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tassos GEORGIOU filed Critical Tassos GEORGIOU
Publication of CY1123942T1 publication Critical patent/CY1123942T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/08—Food product presented as a kit of parts
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/18—Lipids
    • A23V2250/186—Fatty acids
    • A23V2250/1868—Docosahexaenoic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/18—Lipids
    • A23V2250/186—Fatty acids
    • A23V2250/187—Eicosapentaenoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Edible Oils And Fats (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Συνθέσεις που περιλαμβάνουν ωμέγα-3 λιπαρά οξέα για χρήση στη θεραπεία, βελτίωση ή πρόληψη διαφόρων καταστάσεων, διαταραχών και ασθενειών που επιφέρουν βλάβη στο νευρικό σύστημα, όπως η νευροπάθεια του περιφερικού νευρικού συστήματος και το γλαύκωμα.
CY20201100758T 2013-12-19 2020-08-13 Συνθεσεις ωμεγα-3 λιπαρων οξεων για τη θεραπεια ασθενειων που επιφερουν βλαβη στο νευρικο συστημα CY1123942T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2013/077356 WO2015090394A1 (en) 2013-12-19 2013-12-19 Compositions of omega 3 fatty acids to treat diseases which involve damage to the nervous system

Publications (1)

Publication Number Publication Date
CY1123942T1 true CY1123942T1 (el) 2022-03-24

Family

ID=50137601

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100758T CY1123942T1 (el) 2013-12-19 2020-08-13 Συνθεσεις ωμεγα-3 λιπαρων οξεων για τη θεραπεια ασθενειων που επιφερουν βλαβη στο νευρικο συστημα

Country Status (24)

Country Link
US (2) US20160331712A1 (el)
EP (1) EP3082795B1 (el)
JP (1) JP6389893B2 (el)
KR (1) KR101898358B1 (el)
CN (1) CN105828813A (el)
AU (1) AU2013407946B2 (el)
BR (1) BR112016014182A2 (el)
CA (1) CA2934600C (el)
CY (1) CY1123942T1 (el)
DK (1) DK3082795T3 (el)
ES (1) ES2813383T3 (el)
HR (1) HRP20201221T1 (el)
HU (1) HUE050205T2 (el)
IL (1) IL246254B (el)
LT (1) LT3082795T (el)
MX (1) MX2016007803A (el)
MY (1) MY185412A (el)
PH (1) PH12016501159A1 (el)
PL (1) PL3082795T3 (el)
PT (1) PT3082795T (el)
RS (1) RS60862B1 (el)
RU (1) RU2667640C1 (el)
UA (1) UA117274C2 (el)
WO (1) WO2015090394A1 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3586640A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha enriched polyunsaturated fatty acid compositions
CN108721269A (zh) * 2018-07-10 2018-11-02 广东海洋大学 一种epa与dha混合剂在防治焦虑和快感缺乏方面的应用
MX2022005063A (es) * 2019-10-30 2022-08-04 Perfuse Therapeutics Inc Tratamiento de enfermedades oculares con antagonistas de receptor de endotelina.
IL294873A (en) 2020-02-06 2022-09-01 Perfuse Therapeutics Inc Preparations for the treatment of eye diseases
IL307997A (en) 2021-04-30 2023-12-01 Perfuse Therapeutics Inc Pharmaceutical preparations and intravitreal drug delivery systems for the treatment of eye diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060135610A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
US20100254951A1 (en) * 2005-02-22 2010-10-07 Mochida Pharmaceutical Co., Ltd. Nerve Regeneration Promoting Agent
WO2006090745A1 (ja) * 2005-02-22 2006-08-31 Mochida Pharmaceutical Co., Ltd. 神経再生促進剤
EP1973536A2 (en) * 2006-01-05 2008-10-01 Reliant Pharmaceuticals, Inc. Treatment of fatty liver
EP1900378A1 (en) 2006-08-31 2008-03-19 Novartis AG Pharmaceutical compositions for the treatment of fungal infections
WO2010018856A1 (ja) * 2008-08-13 2010-02-18 持田製薬株式会社 カンナビノイド受容体関連疾患の予防／改善または治療剤
BRPI0924012A2 (pt) * 2009-04-17 2019-09-24 Cela Vista Pharmaceuticals Ltd processo para obtenção de uma composição rica em ácidos graxos ômega 3 de um óleo de origem marinha, com um teor de af interior 90 mg/g composição, suplemento nutricional produto alimentar, composição farmacêutica, e, uso de um composto
US20110237548A1 (en) * 2009-07-23 2011-09-29 U.S. Nutraceuticals, Llc D/B/A Valensa International Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome using omega choline
US20110021465A1 (en) * 2009-07-23 2011-01-27 U.S. Nutraceuticals, Llc D/B/A Valensa International Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome
BR112013018839A2 (pt) * 2011-01-25 2016-09-27 Nestec Sa métodos e composições para o tratamento, a redução ou a prevenção de deterioração do sistema visual dos animais
BR112013020802A2 (pt) * 2011-02-18 2016-10-04 Nestec Sa métodos e composições para tratar, reduzir ou impedir dano ao sistema nervoso de animais
WO2012125020A1 (en) * 2011-03-14 2012-09-20 N.V. Nutricia Method for treating neurotrauma
KR101629670B1 (ko) * 2011-09-12 2016-06-13 타소스 지오지우 질환을 치료하기 위한 오메가 지방산의 용도

Also Published As

Publication number Publication date
UA117274C2 (uk) 2018-07-10
CA2934600C (en) 2018-11-20
WO2015090394A1 (en) 2015-06-25
HRP20201221T1 (hr) 2020-11-13
RS60862B1 (sr) 2020-11-30
MY185412A (en) 2021-05-18
EP3082795A1 (en) 2016-10-26
LT3082795T (lt) 2020-11-10
AU2013407946A2 (en) 2016-08-25
DK3082795T3 (da) 2020-08-24
PL3082795T3 (pl) 2020-11-16
ES2813383T3 (es) 2021-03-23
BR112016014182A2 (pt) 2017-08-08
JP2017501169A (ja) 2017-01-12
CA2934600A1 (en) 2015-06-25
US10905671B2 (en) 2021-02-02
JP6389893B2 (ja) 2018-09-12
KR101898358B1 (ko) 2018-09-12
US20160331712A1 (en) 2016-11-17
MX2016007803A (es) 2017-08-10
EP3082795B1 (en) 2020-05-20
US20190192466A1 (en) 2019-06-27
KR20160093729A (ko) 2016-08-08
AU2013407946B2 (en) 2017-09-07
IL246254A0 (en) 2016-07-31
RU2016129079A (ru) 2018-01-24
CN105828813A (zh) 2016-08-03
PT3082795T (pt) 2020-08-27
HUE050205T2 (hu) 2020-11-30
IL246254B (en) 2021-04-29
AU2013407946A1 (en) 2016-08-04
RU2667640C1 (ru) 2018-09-21
PH12016501159A1 (en) 2016-08-15

Similar Documents

Publication Publication Date Title
CY1123942T1 (el) Συνθεσεις ωμεγα-3 λιπαρων οξεων για τη θεραπεια ασθενειων που επιφερουν βλαβη στο νευρικο συστημα
CO2017011535A2 (es) Composiciones de ácido obeticólico y métodos de uso
CL2019000609A1 (es) Variantes de alfa-glucosidasa ácida y usos de las mismas.
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
BR112017001796A2 (pt) composições de flagelina e seus usos
EA201691582A1 (ru) Новые фармацевтические препараты
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
TR201901886T4 (tr) DNA-PK inhibitörleri.
UY34617A (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas
CL2019000610A1 (es) Variantes de alfa-glucosidasa ácida y usos de las mismas.
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
EA201500852A1 (ru) Формы метил {4,6-диамино-2-[1-(2-фторбензил)-1н-пиразоло[3,4-в]пиридино-3-ил]пиримидино-5-ил}метил карбамата
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
CO7350653A2 (es) Retinoides y uso de los mismos
MA40846A (fr) Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'états pathologiques
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
FR3019746B1 (fr) Diffuseur de substances, notamment de parfum, d'huiles essentielles
MX2021001790A (es) Composiciones solidas de trigliceridos y usos de estas.
BR112017007754A2 (pt) composições de ácido graxo monoinsaturado e uso para o tratamento de aterosclerose.
BR112017012810A2 (pt) método para tratamento ou prevenção de doenças associadas à poluição do ar
TR201902864T4 (tr) Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanımı ile azaltılmış merkezi korneal kalınlaşma.
FR3053891B1 (fr) Diffuseur de vapeurs, notamment d'huiles essentielles
FR3019002B1 (fr) Utilisation d'ester(s) d'acide(s) gras comme insecticide.
EA201700030A1 (ru) Липид, содержащий докозапентаеновую кислоту
TH1601003574A (th) ลิปิดซึ่งประกอบรวมด้วยกรดไขมันไม่อิ่มตัวหลายตำแหน่งชนิดสายยาว